4//SEC Filing
Lyon Joseph Douglas 4
Accession 0001193125-25-307229
CIK 0001088856other
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 8:36 PM ET
Size
14.8 KB
Accession
0001193125-25-307229
Insider Transaction Report
Form 4
Lyon Joseph Douglas
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-12-01$13.56/sh+5,000$67,800→ 15,277 total - Sale
Common Stock
2025-12-01$79.53/sh−5,000$397,632→ 10,277 total - Award
Common Stock
2025-12-01$79.78/sh+178$14,201→ 10,455 total - Tax Payment
Common Stock
2025-12-02$79.78/sh−110$8,776→ 10,523 total - Exercise/Conversion
Stock option (right to buy)
2025-12-01−5,000→ 11,571 totalExercise: $13.56Exp: 2030-02-07→ Common Stock (5,000 underlying)
Footnotes (9)
- [F1]Includes 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- [F2]The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.
- [F3]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $79.73 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- [F4]The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025.
- [F5]In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
- [F6]Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
- [F7]These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
- [F8]The closing price on December 1, 2025 was used to calculate the withholding obligation.
- [F9]Fully exercisable.
Documents
Issuer
CORCEPT THERAPEUTICS INC
CIK 0001088856
Entity typeother
Related Parties
1- filerCIK 0001817838
Filing Metadata
- Form type
- 4
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 8:36 PM ET
- Size
- 14.8 KB